tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
TuHURA Biosciences Completes Acquisition of Kineta, Inc.
PremiumCompany AnnouncementsTuHURA Biosciences Completes Acquisition of Kineta, Inc.
3M ago
TuHURA Biosciences Increases Authorized Common Stock Shares
Premium
Company Announcements
TuHURA Biosciences Increases Authorized Common Stock Shares
3M ago
Buy Rating for TuHURA Biosciences: Promising Phase 3 Study and Strategic Merger with Kineta Inc.
Premium
Ratings
Buy Rating for TuHURA Biosciences: Promising Phase 3 Study and Strategic Merger with Kineta Inc.
3M ago
TuHURA Biosciences Approves Executive Salary Increases
PremiumCompany AnnouncementsTuHURA Biosciences Approves Executive Salary Increases
4M ago
TuHURA announces FDA removed partial clinical hold on Phase 3 trial of IFx-2.0
Premium
The Fly
TuHURA announces FDA removed partial clinical hold on Phase 3 trial of IFx-2.0
4M ago
TuHURA Biosciences Secures $12.6M for Strategic Initiatives
Premium
Company Announcements
TuHURA Biosciences Secures $12.6M for Strategic Initiatives
4M ago
Innovative Immune Therapy Approach Drives Buy Rating for TuHURA Biosciences
PremiumRatingsInnovative Immune Therapy Approach Drives Buy Rating for TuHURA Biosciences
5M ago
TuHURA Biosciences initiates Phase 1b/2a study of IFx-Hu2.0 in carcinoma
Premium
The Fly
TuHURA Biosciences initiates Phase 1b/2a study of IFx-Hu2.0 in carcinoma
5M ago
TuHURA Biosciences: Promising Developments in Anti-VISTA Antibody and DNA-based Immune Activator Justify Buy Rating
Premium
Ratings
TuHURA Biosciences: Promising Developments in Anti-VISTA Antibody and DNA-based Immune Activator Justify Buy Rating
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100